Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076011 · ClinicalTrials.gov registry record · Phase 2
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study of Kidney Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 9
- Study locations
NCT00076011: Completed Phase 2 study of Kidney Neoplasms, sponsored by Pfizer.
NCT00076011 is a Phase 2 study of Kidney Neoplasms that has completed, run by Pfizer. The registered enrollment target is 52 participants, below the 382-participant average among 9 other Kidney Neoplasms trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076011, a Phase 2 study of Kidney Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
Primary Outcome
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target les
Conditions Studied
Interventions
- DRUG Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
Study Locations (9)
Massachusetts
- Pfizer Investigational Site - Boston
- Pfizer Investigational Site - Boston
California
- Pfizer Investigational Site - San Francisco
New York
- Pfizer Investigational Site - New York
Ohio
- Pfizer Investigational Site - Cleveland
Pennsylvania
- Pfizer Investigational Site - Philadelphia
Wisconsin
- Pfizer Investigational Site - Madison
Paris
- Pfizer Investigational Site - Paris
Other
- Pfizer Investigational Site - Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00076011 record still lists
NCT00076011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 382-participant average among 9 other Kidney Neoplasms trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Kidney Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor is the first listed.
NCT00076011 lists 9 locations in 8 states (Massachusetts, California, New York).
Frequently Asked Questions
What is clinical trial NCT00076011 about?
NCT00076011 is a clinical study titled "Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma". The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
What is the current status of trial NCT00076011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2003-10. Estimated completion is 2007-02.
What conditions does trial NCT00076011 study?
This clinical trial studies the following conditions: Kidney Neoplasms.
What interventions are being tested in trial NCT00076011?
The interventions under investigation include: Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor (DRUG).
Who is sponsoring clinical trial NCT00076011?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076011 being conducted?
This trial has 9 study locations across California, Massachusetts, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00076011's enrollment target sits among peer trials
52 7th of 9 higher than 3 of 9 other Kidney Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
RECRUITING · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
-
Cabozantinib for Advanced Urothelial Cancer
COMPLETED · Phase 2
-
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
RECRUITING
-
Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach
RECRUITING · NA
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia